Investment Thesis
Zenas BioPharma exhibits strong balance sheet fundamentals with $500.2M cash reserves and low debt (0.23x D/E), but severe operating losses (-$77.3M), deteriorating net income trends (-140.6% YoY), and substantial annual cash burn (-$75.2M) with flat revenue ($10M) indicate a pre-commercial biotech company with no visible near-term profitability.
Strengths
- Strong cash position of $500.2M provides 6-7 years operational runway at current burn rate
- Exceptional liquidity with 11.94x current and quick ratios providing financial flexibility
- Low leverage with 0.23x debt-to-equity ratio and minimal debt burden of $78.6M
Risks
- Severe and deteriorating profitability with -$77.3M operating income and net income declining 140.6% YoY
- Substantial annual cash burn of $75.2M with minimal revenue generation, unsustainable without external funding beyond 6-7 years
- Pre-commercial biotech model with zero revenue growth (0% YoY) and no demonstrated path to profitability; subject to typical biotech execution risks
Key Metrics to Watch
- Operating cash burn rate and depletion of cash reserves
- Revenue inflection point and growth trajectory toward sustainability
- Operating margin trend and progress toward breakeven profitability
Financial Metrics
Revenue
10.0M
Net Income
-81.0M
EPS (Diluted)
$-1.46
Free Cash Flow
-75.2M
Total Assets
747.7M
Cash
500.2M
Profitability Ratios
Gross Margin
N/A
Operating Margin
-773.5%
Net Margin
-809.9%
ROE
-24.1%
ROA
-10.8%
FCF Margin
-752.0%
Balance Sheet & Liquidity
Current Ratio
11.94x
Quick Ratio
11.94x
Debt/Equity
0.23x
Debt/Assets
55.1%
Interest Coverage
-210.19x
Long-term Debt
78.6M
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-23T09:48:20.413696 |
Data as of: 2026-03-31 |
Powered by Claude AI